Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

ProQR Therapeutics (PRQR) Receivables - Net (2022 - 2025)

ProQR Therapeutics' Receivables - Net history spans 3 years, with the latest figure at $7.9 million for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 97.69% to $7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.9 million, a 97.69% increase, with the full-year FY2025 number at $7.9 million, up 97.69% from a year prior.
  • Receivables - Net hit $7.9 million in Q4 2025 for ProQR Therapeutics, up from $4.0 million in the prior quarter.
  • Over the last five years, Receivables - Net for PRQR hit a ceiling of $57.4 million in Q4 2022 and a floor of $4.0 million in Q4 2024.
  • Historically, Receivables - Net has averaged $23.1 million across 3 years, with a median of $7.9 million in 2025.
  • The widest YoY moves for Receivables - Net: up 97.69% in 2025, down 97.69% in 2025.
  • Tracing PRQR's Receivables - Net over 3 years: stood at $57.4 million in 2022, then crashed by 93.02% to $4.0 million in 2024, then skyrocketed by 97.69% to $7.9 million in 2025.
  • Business Quant data shows Receivables - Net for PRQR at $7.9 million in Q4 2025, $4.0 million in Q4 2024, and $57.4 million in Q4 2022.